2. Appendix Tables legend General Legend applicable for Table S1 to S4 (Page 10)

Transcription

1 Appendix Data The hvps- signalling module counteracts inhibition of the PIK-Akt pathway to maintain mtorc activity and tumour growth Ruzica Bago, Eeva Sommer, Pau Castel, Claire Crafter, Fiona P. Bailey, Natalia Shpiro, José Baselga, Darren Cross, Patrick A. Eyers and Dario R. Alessi Table of Contents:. Appendix Tables Appendix Figure S (Page ) Appendix Figure S (Page ) Appendix Figure S (Page ) Appendix Figure S (Page 5) Appendix Table S. Sanofi g (Page 6) Appendix Table S. Sanofi h (Page 7) Appendix Table S. Sanofi i (Page 8) Appendix Table S. Sanofi n (Page 9). Appendix Tables legend General Legend applicable for Table S to S (Page )

2 A g i n B. kinase g i n MLK MLK PKBa > > >.76 Appendix Figure S. Structure and IC5 data for g, i and n SGK inhibitors. (A) Chemical structures of Sanofi-g, -i and -n compounds. (B) IC5 values of inhibitors on indicated recombinant kinases.

3 5 A μm) MLK TIE 9 6 DYRK MAPKAP-K PHK SIK TTBK CK_ IGF-R IR EIFAK EPH-A PRK PKCa SRPK ZAP7 RIPK PIM MST CLK PKC_ MAPKAP-K SIK OSR p8a MAPK WNK TTBK DDR PIM FGF-R EPH-B TGFBR CK_ JAK NEKa IRAK MARK B GSKb CAMKKb EFK MNK DYRK PAK EPH-B PDGFRA EPH-B JNK PRAK Src TESK NEK6 IKKb ABL SYK ERK ULK HER PLK MPSK VEG-FR PINK ASK TSSK Aurora A ERK5 MARK MNK PIM MKK p8g MAPK CDK9-Cyclin T MKK6 STK SmMLCK MARK JNK HIPK LKB PKBa EPH-B Aurora B PAK6 MST BRK PKBb JNK PKCz MEKK p8b MAPK MKK DYRKA CK TAO Lck MST EPH-A YES AMPK (hum) PKA TrkA IRR BTK CDK-Cyclin A DAPK ULK TLK p8d MAPK ROCK HIPK MARK PKD IRAK RSK PAK5 CSK TBK BRSK TTK ERK CHK CHK MELK TAK MINK IKKe NUAK MAPK GCK HIPK CAMK MAPK5 PAK ERK8 MLK TIE MLK 5 B μm) HIPK MLK TIE 9 6 PIM TTBK DYRK PHK Src IGF-R TGFBR CAMKKb LKB CK_ MNK MARK IRAK MPSK TTBK ZAP7 BRK Aurora A CDK9-Cyclin T IR OSR NEKa MST PKCa SIK EFK SIK SRPK JNK TESK p8g MAPK IKKb PIM PKBa ABL GSKb PIM DAPK TSSK MARK DDR STK MST PKA PKBb PKCz ERK5 MAPKAP-K B PAK NEK6 ERK JNK MKK PRK ERK p8a MAPK CK_ ASK PINK EPH-A EPH-A EPH-B EPH-B ULK DYRKA PAK6 CLK EPH-B ULK WNK EPH-B PKC_ MAPKAP-K PRAK ROCK PLK YES RIPK p8d MAPK MKK6 HER SmMLCK MARK FGF-R MEKK RSK BTK IRR JNK p8b MAPK MKK DYRK Lck PKD BRSK CK Aurora B MARK CDK-Cyclin A MNK CSK SYK AMPK (hum) IKKe TLK JAK MELK EIFAK IRAK TrkA HIPK CHK TAO CHK TTK MINK VEG-FR PAK5 MST CAMK MAPK NUAK TAK TBK PDGFRA HIPK ERK8 GCK MAPK5 PAK MLK HIPK MLK TIE 5 C μm) TIE MLK MLK 9 6 ASK HER CDK9-Cyclin T EPH-B MARK PAK PRAK MAPKAP-K DAPK Aurora A PIM TLK Src EPH-B FGF-R TESK RIPK EPH-A TrkA TTBK PINK MARK ROCK PHK MARK ABL JNK MAPKAP-K SmMLCK MEKK EPH-B PIM BRK PKB beta PKA PKC alpha CK delta IKK beta HIPK MST WNK ERK5 CDK-Cyclin A TTBK DYRK Lck DDR CK IRAK IRAK CSK IRR ERK PKC gamma ULK EPH-B p8 gamma MAPK PRK SIK EFK MST CHK IR DYRKA NEKa HIPK GSK beta CK gamma DYRK MST OSR MKK6 ERK CAMKK beta B SIK TSSK EPH-A PKB alpha PLK MARK SRPK MPSK p8 alpha MAPK p8 beta MAPK PIM PKC zeta BRSK NEK6 JNK p8 delta MAPK LKB CLK ZAP7 JNK ULK STK YES SYK PKD PAK6 TBK EIFAK BTK IGF-R PAK5 MKK MNK TGFBR JAK VEGFR RSK MNK AMPK (hum) MELK MKK TAO MINK PDGFRA TTK IKK epsilon CHK NUAK HIPK CAMK ERK8 PAK Aurora B MAPK TAK GCK MAPK5 TIE MLK MLK Appendix Figure S. Protein kinase profiling of g, i and n SGK inhibitors. Profiling of Sanofi g (A), i (B) and n (C) compounds was undertaken against the Dundee panel of protein kinases in the presence of µm compound at the International Centre for protein Kinase Profiling. The result for each kinase is presented as a mean kinase activity of the reaction taken in triplicate relative to a control reaction where the inhibitors were omitted. Abbreviations and assay conditions are described at

4 log mrna copies counted log mrna copies counted log mrna copies counted log mrna copies counted DMSO AKT PKN MAST ROCK MK-6 MSK ADRBK NDR LATS RSK PKG SGK AKT PKN MAST ROCK ADRBK MSK NDR LATS RSK SGK PKG AZD56 AKT PKN MAST ROCK MSK ADRBK NDR LATS RSK SGK PKG GDC9 AKT PKN MAST ROCK ADRBK NDR MSK LATS RSK PKG SGK MAST Appendix Figure S. Human AGC kinase mrna expression profiles in cells exposed to compounds for days. ZR-75- cells were grown in the presence or absence of DMSO, µm MK-6, µm AZD56 or µm GDC9 for days, and total human AGC kinase mrna levels were quantified using NanoString software. Data are presented as log values of triplicate data ± SD. The rank order position of mrna in each condition is annotated in red (left panel). All AGC kinase mrnas exhibiting a -fold change in expression level in the appropriate compound relative to DMSO control are quantified (right panel). =p<.5, =p<., =p<. (right panel).

5 log mrna copies counted log mrna copies counted log mrna copies counted log mrna copies counted DMSO AKT PKN MAST ROCK MSK ADRBK NDR LATS RSK SGK PKG MK-6 AKT PKN MAST ROCK MSK ADRBK NDR LATS RSK SGK PKG AZD56 AKT PKN MAST ROCK MSK ADRBK NDR LATS RSK SGK PKG GDC9 AKT PKN MAST ROCK MSK ADRBK NDR LATS RSK SGK PKG MAST Appendix Figure S. Human AGC kinase mrna expression profiles in cells exposed to compounds for 5 days. ZR-75- cells were grown in the presence or absence of DMSO, µm MK-6, µm AZD56 or µm GDC9 for 5 days, and total human AGC kinase mrna levels were quantified using NanoString software. Data are presented as log values of triplicate data ± SD. The rank order position of mrna in each condition is annotated in red (left panel). All AGC kinase mrnas exhibiting a -fold change in expression level in the appropriate compound relative to DMSO control are quantified (right panel). =p<.5, =p<. (right panel). 5

6 Appendix Table S. Sanofi-g kinase % activity kinase % activity kinase % activity DYRK MAPKAP-K 7 PHK 5 SIK 5 TTBK CK delta IGF-R EIFAK EPH-A IR PRK 9 PKC alpha 8 SRPK 8 ZAP7 8 PIM 7 RIPK 7 6 PKC gamma 6 CLK 6 MST 6 MAPKAP-K 5 SIK 5 OSR 5 p8 alpha TTBK WNK CK gamma NEKa PIM TGFBR JAK EPH-B FGF-R DDR MARK B IRAK GSK beta MNK CAMKK beta DYRK EFK PAK 9 EPH-B 9 JNK 8 EPH-B 8 PDGFRA 8 PRAK 7 NEK6 7 IKK beta 7 TESK 7 Src 7 ABL 7 SYK 6 ERK 5 ULK 5 HER 5 PLK MPSK VEGFR ASK PINK ERK5 MNK Aurora A MARK TSSK MKK MKK6 p8 gamma STK SmMLCK CDK9-Cyclin PIM JNK PKB alpha LKB MARK HIPK Aurora B 99 PAK6 99 MST 99 BRK 99 EPH-B 99 JNK 98 p8 beta 98 PKB beta 98 PKC zeta 98 MEKK 98 MKK 97 DYRKA 97 CK 96 TAO 96 MST 95 Lck 95 PKA 9 AMPK 9 YES 9 EPH-A 9 TrkA 9 CDK-Cyclin 9 BTK 9 IRR 9 DAPK 9 TLK 9 ULK 9 p8 delta 89 ROCK 89 HIPK 88 PKD 86 MARK 86 RSK 85 PAK5 85 IRAK 85 CSK 85 TBK 8 BRSK 8 ERK 8 TTK 8 CHK 79 CHK 79 MELK 79 TAK 79 MINK 77 IKK epsilon NUAK 7 MAPK 67 GCK HIPK 5 CAMK PAK 9 MAPK5 9 ERK8 MLK 8 MLK 5 TIE 5 9 6

7 Appendix Table S. Sanofi-h kinase % activity kinase % activity kinase % activity MARK CSK 9 CK 8 MAPKAP-K ASK ERK5 9 p8 alpha 7 ROCK 7 EPH-A 7 Src 5 FGF-R 5 p8 delta MAPKAP-K MEKK MPSK CHK TLK PKC gamma PIM TESK Lck EPH-A TTBK PAK ZAP7 PKA 9 PHK 9 DYRK 9 PLK 8 SRPK 8 IRAK 8 PRAK 7 CDK9-Cyclin 7 PKC alpha 6 MARK 6 PKB alpha 5 STK 5 DAPK 5 NEK6 5 IRR 5 DDR 5 p8 gamma MNK CDK-Cyclin B MST NEKa WNK EPH-B HER JNK SIK PIM SmMLCK SIK PAK6 SYK TrkA JNK CAMKK beta Aurora A CK delta TTBK IKK beta PIM ULK BRK ERK 99 TSSK 99 MST 99 OSR 99 EPH-B 99 EPH-B 99 PINK 99 PKB beta 98 EFK 98 HIPK 98 EPH-B 98 p8 beta 97 PKC zeta 97 MNK 97 GSK beta 97 LKB 97 BRSK 97 IGF-R AMPK 96 ERK 95 MARK 95 MARK 95 RIPK 95 YES 95 JNK 9 DYRKA 9 DYRK 9 TBK 9 HIPK 9 MKK6 9 MST 9 CLK 9 TAO 9 IRAK 9 ABL 9 PRK 89 BTK 89 PDGFRA 89 PKD 87 PAK5 87 ULK 8 IR 8 CK gamma 8 EIFAK 8 TGFBR 78 RSK 77 TTK 77 JAK 77 VEGFR 7 MKK 7 MINK 7 MKK 7 IKK epsilon 69 MELK 67 CAMK 6 NUAK 6 CHK 5 8 PAK 6 HIPK 5 TAK 5 Aurora B ERK8 8 GCK MAPK 5 MAPK5 MLK TIE 6 MLK 6 7

8 Appendix Table S. Sanofi-i kinase % activity kinase % activity kinase % activity PIM TTBK DYRK PHK Src IGF-R 9 TGFBR 8 CAMKK beta 7 LKB 7 MNK 6 MARK 6 CK delta 6 IRAK MPSK TTBK ZAP7 CDK9-Cyclin Aurora A BRK IR OSR NEKa 9 PKC alpha 8 MST 8 SIK 7 SIK 7 SRPK 7 EFK 7 JNK 6 p8 gamma 5 IKK beta 5 PIM 5 TESK 5 PKB alpha GSK beta PIM ABL DAPK MARK TSSK DDR STK MST ERK5 PKB beta PKA PKC zeta MAPKAP-K B NEK6 PAK MKK 99 ERK 99 ERK 99 JNK 99 PRK 99 p8 alpha 98 CK gamma 98 DYRKA 98 PAK6 98 ASK 98 ULK 98 EPH-A 98 EPH-A 98 EPH-B 98 EPH-B 98 PINK 98 PKC gamma 97 MAPKAP-K 97 PRAK 97 CLK 97 WNK 97 ULK 97 EPH-B 97 EPH-B 97 ROCK 96 PLK 96 YES 95 MKK6 9 p8 delta 9 9 RIPK 9 HER 9 SmMLCK 9 RSK 9 MARK 9 MEKK 9 BTK 9 FGF-R 9 JNK 9 p8 beta 9 IRR 9 MKK 9 DYRK 9 PKD 88 Lck 88 Aurora B 87 BRSK 87 CK 87 MARK 86 CDK-Cyclin 85 MNK 8 CSK 8 SYK 8 AMPK 8 IKK epsilon 8 TLK 8 MELK 8 JAK 8 EIFAK 8 IRAK 8 TrkA 79 HIPK 78 CHK 75 TAO 75 CHK 7 TTK 7 PAK5 68 MINK 68 VEGFR 68 MST 67 CAMK 66 MAPK 66 NUAK 65 TAK 6 TBK 6 PDGFRA 55 HIPK 7 ERK8 GCK MAPK5 9 PAK MLK HIPK 5 MLK TIE 9 5 8

9 Appendix Table S. Sanofi-n kinase % activity kinase % activity kinase % activity ASK HER 9 CDK9-Cyclin 5 EPH-B MARK PAK PRAK MAPKAP-K DAPK Aurora A PIM TLK 9 Src 9 EPH-B 9 FGF-R 9 TESK 8 RIPK 8 EPH-A 8 TrkA 8 TTBK 7 PINK 7 MARK 6 ROCK 5 PHK 5 MARK 5 ABL 5 JNK MAPKAP-K SmMLCK MEKK EPH-B PIM BRK PKB beta PKA PKC alpha CK delta IKK beta HIPK MST WNK ERK5 CDK-Cyclin TTBK DYRK Lck DDR CK IRAK IRAK CSK IRR ERK 99 PKC gamma 99 ULK 99 EPH-B 99 p8 gamma 98 PRK 98 SIK 98 EFK 98 MST 98 IR 98 CHK 97 DYRKA 97 NEKa 96 HIPK 96 GSK beta 95 CK gamma 95 DYRK 95 MST 95 OSR 95 MKK6 9 ERK 9 CAMKK beta 9 B 9 SIK 9 TSSK 9 EPH-A 9 PKB alpha 9 PLK 9 MARK 9 SRPK 9 MPSK 9 p8 alpha 9 p8 beta 9 PIM 9 PKC zeta 9 BRSK 9 NEK6 9 JNK 9 p8 delta 9 LKB 9 CLK 9 ZAP7 9 JNK 89 ULK 89 STK 88 YES 88 SYK 88 PKD 87 PAK6 86 TBK 8 EIFAK 8 BTK 8 IGF-R 8 PAK5 8 MKK 8 MNK 8 TGFBR 8 JAK 8 VEGFR 8 RSK 79 MNK 79 AMPK 79 MELK 78 MKK 77 TAO 77 MINK 75 PDGFRA 7 TTK 7 IKK epsilon 67 CHK 6 NUAK 6 HIPK 6 56 CAMK 56 ERK8 5 PAK 7 Aurora B 9 MAPK 9 TAK 8 GCK MAPK5 TIE MLK 8 6 MLK 6 9

10 Appendix Table legend General Legend applicable for Table S to S (Pages 6 to 9) Results are presented as the percentage of kinase activity in DMSO control reactions. Protein kinases were assayed in vitro in the presence of μm Sanofi-g (Table ), -h (Table ), -i (Table ) and -n (Table ) compounds, as described on the International Centre for Kinase Profiling website ( and the results are means ± S.D. for triplicate reactions. Abbreviations are as follows: ABL, Abelson tyrosine-protein kinase ; AMPK, AMPactivated protein kinase; ASK, apoptosis signal-regulating kinase; BRK, breast tumour kinase; BRSK, brain-specific kinase; BTK, Bruton s tyrosine kinase; CaMK, calmodulindependent kinase; CaMKK, CaMK kinase; CDK, cyclin-dependent kinase; CHK, checkpoint kinase; CK, casein kinase; CLK, CDC-like kinase; CSK, C-terminal Src kinase; DAPK, death-associated protein kinase; DDR, discoidin domain receptor; DYRK, dualspecificity tyrosine-phosphorylated and regulated kinase; EFK, elongation-factor- kinase; EIFAK, eukaryotic translation initiation factor -alpha kinase; EPH, ephrin; ERK, extracellular signal-regulated kinase; FGF-R, fibroblast growth factor receptor; GCK, germinal centre kinase; GSK, glycogen synthase kinase; HER, human epidermal growth factor receptor; HIPK, homeodomain-interacting protein kinase; IGFR, IGF receptor; IKK, inhibitory κb kinase; IR, insulin receptor; IRAK, interleukin- receptorassociated kinase; IRR, insulin-related receptor; JAK, Janus kinase; JNK, c-jun N-terminal kinase; Lck, lymphocyte cell-specific protein tyrosine kinase; LKB, liver kinase B; MAPK, mitogen-activated protein kinase; MAPKAP-K, MAPK-activated protein kinase; MARK, microtubule-affinity regulating kinase; MEKK, MAP kinase kinase kinase; MELK, maternal embryonic leucinezipper kinase; MINK, misshapen/nik-related kinase; MKK, MAPK kinase; MLK, mixed lineage kinase; MNK, MAPK-integrating protein kinase; MPSK, myristoylated and palmitoylated serine/threonine-protein kinase; MSK, mitogen- and stress-activated protein kinase; MST, mammalian homologue Ste-like kinase; NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase; NUAK, novel (NUA) family SnF-like kinase; OSR, oxidative stress-responsive kinase; PAK, p- activated protein kinase; PDGFRA, platelet-derived growth factor receptor-α; PDK, phosphoinositide-dependent kinase; PHK, phosphorylase kinase; PIM, provirus integration site for Moloney murine leukaemia virus; PINK (insect homologue), PTENinduced kinase; PKA, camp-dependent protein kinase; PKB, protein kinase B; PKC, protein kinase C; PKD, protein kinase D; PLK, polo-like kinase; PRAK, p8-regulated activated kinase; PRK, protein kinase C-related kinase; RIPK, receptor-interacting protein kinase; ROCK, Rho-dependent protein kinase; RSK, ribosomal S6 kinase;, p7 ribosomal S6 kinase; SGK, serum- and glucocorticoid-induced protein kinase; SIK, salt-induced kinase; smmlck, smooth muscle myosin light-chain kinase; SRPK, serine/arginine protein kinase; STK, serine/threonine kinase; SYK, spleen tyrosine kinase; TAK, TGFβ-activated kinase; TAO, thousand and one amino acid; TBK, TANKbinding kinase ; TESK, testis-specific protein kinase; TGFBR, TGFβ receptor; TIE, tyrosine-protein kinase receptor; TLK, tousled-like kinase; TrkA, tropomyocin receptor kinase; TSSK, testis-specific serine/threonine-protein kinase; TTBK, tau-tubulin kinase; ULK, Unc-5-like kinase; VEGFR, vascular endothelial growth factor receptor; WNK, with no lysine; YES, Yamaguchi sarcoma viral oncogene homologue ; ZAP, ζ-chainassociated protein.